

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/028532 A1

(51) International Patent Classification⁷: A61K 31/4045, A61P 25/00

(21) International Application Number:
PCT/EP2003/010827

(22) International Filing Date:
26 September 2003 (26.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02021810.3 26 September 2002 (26.09.2002) EP

(71) Applicant (for all designated States except US):
POOGER PROPERTIES LIMITED [GB/GB]; c/o
Grant Thornton Stenhouse Ltd., P.O. Box 639, St. Helier,
Jersey JE1 4HH (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): KRUISINGA,
Roelof, Johannes, Hendrik [NL/NL]; Prins Frederiklaan
6, NL-2243 HW Wassenaar (NL).

(74) Agent: HUYGENS, Arthur, V.; Octrooibureau Huygens,
P.O. Box 86, NL-3400 AB IJsselstein (NL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/028532 A1

(54) Title: COMBINED USE OF METHYLPHENIDATE AND MELATONIN FOR TREATING ATTENTION-DEFICIT HYPERACTIVE DISORDER

(57) Abstract: The present invention relates to the combined use of methyl phenidate and at least one of melatonin, a melatonin analogue, or a pharmaceutically acceptable salt thereof in the treatment of attention deficit hyperactive disorder (ADHD). Methylphenidate and melatonin or its analogue may be used together or in combination with one or more other active ingredients, and is preferably formulated as a composition for controlled release.

10/529341

JC17 Rec'd PCT/PTO 25 MAR 2005

Combined use of methylphenidate and melatonin for treating**Attention-Deficit Hyperactive Disorder**

The present invention relates a to the combined use of methylphenidate and
5 melatonin for the treatment of attention-deficit hyperactivity disorder ("ADHD") in
mammals, including humans. The invention relates also to a pharmaceutical composition
comprising methylphenidate and melatonin.

As described in EP-A-0 896 536, ADHD is a condition affecting a significant
proportion of children and which is manifest by learning difficulties, restlessness, inability
10 to settle to any task, argumentativeness, low frustration tolerance and aggressive conduct.
A traditional method of treating such children was by administration of psychostimulant
such as methylphenidate.

Methylphenidate, also known under the trademark Ritalin®, is a medication
prescribed for individuals (usually children) who have an abnormally high level of activity
15 or attention-deficit hyperactivity disorder (ADHD). According to the U.S. National Institute
of Mental Health, about 3 to 5 percent of the general population in the U.S.A. has the
disorder, which is characterized by agitated behavior and an inability to focus on tasks.
Methylphenidate also is occasionally prescribed for treating narcolepsy.

Methylphenidate is a central nervous system (CNS) stimulant. It has effects
20 similar to, but more potent than, caffeine and less potent than amphetamines. It has a
notably calming effect on hyperactive children and a "focusing" effect on those with ADHD.

Recent research at Brookhaven National Laboratory may begin to explain how
methylphenidate helps people with ADHD. The researchers used positron emission
tomography (PET - a noninvasive brain scan) to confirm that administering normal
25 therapeutic doses of methylphenidate to healthy, adult men increased their dopamine
levels. The researchers speculate that methylphenidate amplifies the release of dopamine,
a neurotransmitter, thereby improving attention and focus in individuals who have
dopamine signals that are weak, such as individuals with ADHD. See, N. Volkow et al., *J*
of Neuroscience (2001) 21:RC121:1-5.

30 While psychostimulants are useful in increasing attention spans, they have
major side-effects, including loss of appetite and insomnia and do not deal with the
problems of hyperactivity.

The aforementioned EP-A-0 896 536 discloses the use of lofexidine, 2-[α -(2,6-
dichlorophenoxy)ethyl- Δ^2 -imidazole, in the manufacture of a medicament for treating
35 ADHD, which reportedly does not incur the same level of side-effects as clonidine. The

latter compound (see Hunt *et al.*, Journal of the American Academy of Child Adolescent Psychiatry 24 (1995)) has been shown to be effective in treating ADHD, but it may also cause hypotension and a high level of sedation as a side-effect. It is stated in said EP reference that while a measure of sedation can be useful in the treatment of hyperactive
5 children, it does not assist in increasing attention span.

Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous hormone of the pineal gland, a small organ (approx. 100 mg) located in the mid-brain above the third ventricle (A.B. Lerner *et al.*, *J. Amer. Chem. Soc.* 1958; 80:2587). The rate-limiting enzyme for its synthesis, N-acetyltransferase (NAT) is produced only during the night.
10 Night-time values of NAT are more than 100-fold greater than daytime levels. Melatonin is also produced by extra-pineal tissues, that lightens skin color in amphibians by reversing the darkening effect of MSH (melanotropin). Melatonin has been postulated as the mediator of photic-induced anti-gonadotropic activity in photoperiodic mammals and has also been shown to be involved in thermoregulation in some ectotherms and in affecting
15 locomotor activity rhythms in sparrows.

Melatonin, when used experimentally, is synthesised chemically and has been studied extensively in clinical and preclinical trials to examine the effects of the circadian SCN clock (A.J. Lewy *et al.*, *Behav. Brain Res.* 1996; 73:1-2 131-4).

Non-prepublished international patent application PCT/EP02/03317 discloses
20 that melatonin has usefulness in the treatment of ADHD, and provides the use of at least one of melatonin, a melatonin analogue, or a pharmaceutically acceptable salt of melatonin or said melatonin analogue, in the preparation of a medicament for the treatment of ADHD in mammals, in particular human beings.

The present invention is based on the surprising finding that the combined use
25 of methylphenidate and melatonin has a beneficial effect on the treatment of ADHD, which will frequently exceed the effect of the individual active compounds.

Accordingly, the present invention provides the combined use of methylphenidate and melatonin in any form for the treatment of ADHD in mammals, in particular human beings, especially children.

30 As used hereinafter, unless stated otherwise, the term "melatonin" includes melatonin per se, a melatonin analogue, i.e. a substance exhibiting high affinity for melatonin receptors, or a pharmaceutically acceptable salt of melatonin or a melatonin analogue.

The medicament for the treatment of ADHD comprising the combination of
35 methylphenidate and melatonin as active ingredients is suitably administered to the

mammal in the form of a pharmaceutical composition. The administration may be by way of oral or parenteral administration.

The medicament can be administered in conventional form for oral administration, e.g. as tablets, lozenges, dragees and capsules. However, for the
5 administration of the drug to children, which is likely to be its major use, it may be preferred to formulate the composition as an oral liquid preparation such as a syrup, a nasal spray, or a suppository. The medicament can also be administered parenterally, e.g. by intramuscular or subcutaneous injection, using formulations in which the medicament is employed in a saline or other pharmaceutically acceptable, injectable composition.

10 An amount effective to treat the disorder hereinbefore described depends on the usual factors such as the nature and severity of the disorder being treated, the weight of the mammal, the specific compounds of choice, and considerations and preferences of the prescriber. The amount of active ingredients to be administered usually will be in the range of nanograms to 50 mg or more per dose. However, a unit dose will normally
15 contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50, 100, 200, 300 and 400 mg of the active ingredient. Unit doses will normally be administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult, of 1 to 1000 mg, for example 1 to
20 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6 mg/kg/day.

It is greatly preferred that the combination of methylphenidate and melatonin according to the invention is administered in the form of a unit-dose composition, such as a unit dose oral, such as sub-lingual, rectal, topical or parenteral (especially intravenous)
25 composition.

Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are
30 preferred, in particular shaped oral compositions, since they are more convenient for general use. The preparation of such compositions is well known to people skilled in the art and can be optimized in a routine way without exerting inventive skill and without undue experimentation.

Tablets and capsules for oral administration are usually presented in a unit
35 dose, and contain conventional excipients such as binding agents, fillers, diluents,

tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

Suitable fillers for use include, mannitol and other similar agents. Suitable disintegrants include starch derivatives such as sodium starch glycollate. Suitable
5 lubricants include, for example, magnesium stearate.

These solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

10 Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose,
15 aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

20 Oral formulations further include controlled release formulations which may also be useful in the practice of this invention. The controlled release formulation may be designed to give an initial high dose of the active material and then a steady dose over an extended period of time, or a slow build up to the desired dose rate, or variations of these procedures. Controlled release formulations also include conventional sustained release
25 formulations, for example tablets or granules having an enteric coating.

Nasal spray compositions are also a useful way of administering the pharmaceutical preparations of this invention to patients such as children for whom compliance is difficult. Such formulations are generally aqueous and are packaged in a nasal spray applicator which delivers a fine spray of the composition to the nasal
30 passages.

Suppositories are also a traditionally good way of administering drugs to children and can be used for the purposes of this invention. Typical bases for formulating suppositories include water-soluble diluents such as polyalkylene glycols and fats, e.g. cocoa oil and polyglycol ester or mixtures of such materials.

For parenteral administration, fluid unit dose forms are prepared containing the active compounds and a sterile vehicle. The active compounds, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before
5 filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.

Parenteral suspensions are prepared in substantially the same manner except that the active compounds are suspended in the vehicle instead of being dissolved and sterilised usually by exposure to ethylene oxide before suspending in the sterile vehicle.
10 Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the combined active compounds of the invention.

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

The present invention further provides a pharmaceutical composition
15 comprising methylphenidate and at least one of melatonin, a melatonin analogue, or a pharmaceutically acceptable salt of melatonin or said melatonin analogue, and a pharmaceutically acceptable carrier. These pharmaceutical compositions may be prepared in a manner known per se or in the manner as hereinbefore described.

In the treatment of ADHD patients in accordance with the invention, methyl-
20 phenidate and melatonin can be used simultaneously or subsequently, preferably melatonin after methylphenidate in the latter case, optionally together with other active materials. The latter materials are preferably chosen such that either their activity is enhanced, preferably in a synergistic way, or undesired side-effects are suppressed by melatonin. For example, melatonin which can be used in conjunction with another active
25 ingredient may additionally contain, besides methylphenidate, one or more substances selected from the group of stimulants, hormones, analogues of such hormones, phyto-hormones, analogues of such phyto-hormones like phyto-estrogen, and anti-oxidants like phyto-vitamins C and E, flavonoids.

The recommended dosages of methylphenidate are well-documented in the
30 art. For example, suitable dosages of methylphenidate which is usually but not exclusively administered as its chloride, include unit-dosages of about 10 mg. The dosage is individual and depends inter alia on the indication. For example, the average dose in the treatment of narcolepsia usually is a tablet of 10 mg twice or three times a day. As another example, the dosage to treat hyperkinetic syndrome with children from the age of about 6 years

starts with about 0.25 mg per kg body weight orally per day (for example 5 mg in the morning and in the afternoon = ½ tablet). This dose may be doubled weekly up to about 2 mg per kg body weight per day, but usually not exceeding 60 mg per day.

Preliminary investigations show the following dose rates for melatonin. For the
5 occasional self-treatment of mild insomnia in adults: 0.3 to 3 mg oral or sublingual dosage (PO), in the evening hours approximately 1 to 2 hours before habitual bedtime. May take up to 6 mg PO if needed. For the adjunctive treatment of insomnia related to major depression: Adults: 5 to 10 mg oral extended release formulations (PO) taken 1 to 2 hours prior to habitual bedtime. In one 4-week placebo-controlled study of 19 patients with major
10 depressive disorder treated with fluoxetine, the sub-group of 10 patients who received concomitant slow-release melatonin at 9 pm for sleep reported significantly improved sleep quality scores versus the patients receiving fluoxetine alone. Melatonin treatment avoided the need for additional sleep medications. No differences in the rates of improvement of depressive symptoms or side effects were reported between the two
15 groups. (Dolberg et al; 1998)

For the treatment of delayed sleep phase syndrome resulting from circadian rhythm disruption, including patients with autism, blindness, Rett's syndrome, or developmental disabilities in adults: Doses of 5 to 7 mg oral immediate release formulations (PO) once daily at bedtime have been used in the blind to entrain circadian
20 rhythms to a 24-hour day. (Sack et al; 1991); in children: Doses of 2.5 to 7.5 mg PO once daily before expected bedtime have been used. The average onset of sleep occurred within 1 hour of melatonin administration. Most children were on concomitant anti-convulsant therapies. Melatonin was administered nightly for up to 4 weeks and appeared to be well tolerated.

25 In the Netherlands melatonin is an "over de counter" hormone product as in the USA, which is to be sold without restrictions in dosages ranging from 0.1 to 0.3 mg. Melatonin is supplied in various grades. Toxic effects have not been reported. At a dose of 240 mg retarded responses have been described (H.R. Lieberman, et al., *Brain Research* (1984) 323:201-207).

30 ADHD is a behaviour disorder with concomitant insomnia in 54% of the cases (D. Efron et al., *Pediatrics* (1997) 100(4) 662-666. In treating ADHD patients with methyl phenidate the problems relating to insomnia have increased to 64% (A.R. Adesman et al., *Pediatrics Clinics North America* (1999) 46(5):945-963. Some authors attribute ADHD behaviour to insufficient sleep (M. Thunström, *Acta Paediatrica* (2002) 91:584-592). The

most plausible hypothesis for a pervasive ADHD-syndrome is likely to be found in a disturbed transfer of stimuli (at noradrenergous/serotenergous level) at various locations in the brain (inter alia at prefrontal, stratial, and even cerebellum levels). See, M. Mercugliano, *Pediatric Clinics of North America* (1999) 46:5 831-843.

5 In a pilot study it was already demonstrated that melatonin 3 mg gave a significant reduction in the time for insomnia for patients who had been previously treated with methyl phenidate (C.V. Tjon Pian Gi et al., poster presentation, *Annual Scientific Meeting European Society for Pediatric Research*, September 2002.

 It has now been found that pure melatonin 2.5 mg is active as a sleep-inducing
10 agent to ADHD patients with insomnia disorders who had been first treated with methyl phenidate.

 The present invention is therefore further characterised in that methyl phenidate and melatonin are applied together, i.e. simultaneously or subsequently, in treating ADHD in mammals, in particular humans and more in particular children. It is
15 preferred that melatonin is administered following the administration of methyl phenidate.

 The amounts of methylphenidate and melatonin may be decreased individually as compared with the normal individual use of these active ingredients to reach a similar or even better effect by the combined use than with the individual components.

 Although the invention has been described primarily as a therapy for children,
20 it can also be used for adults, although dosage rates may be different in the case of adults. Adaptation and optimization of dosages can be readily achieved by skilled persons without undue experimentation.

Claims

1. Use of methylphenidate and at least one of melatonin, a melatonin
analogue, or one or more pharmaceutically acceptable salts or esters thereof, in the
preparation of a medicament for the treatment of ADHD in a mammal, especially a human
5 being.

2. Use as claimed in claim 1 wherein the melatonin or melatonin analogue is
employed in an amount of from 0.005 to 1.00 mg/kg in treating ADHD.

10 3. Use as claimed in any one of the preceding claims wherein the medicament
is formulated as a controlled release preparation.

4. Use as claimed in any one of the preceding claims wherein the medicament
is formulated as a solid oral formulation.

15 5. Use as claimed in any one of the preceding claims wherein the medicament
additionally contains one or more substances selected from the group of stimulants,
hormones, analogues of such hormones, phyto-hormones, analogues of such phyto-
hormones, and anti-oxidants.

20 6. A method of preventing or treating ADHD disorder in a mammal, in
particular a human, which comprises administering to said mammal a therapeutically
effective amount of methylphenidate and one of melatonin, a melatonin analogue, or one
or more pharmaceutically acceptable salts or esters thereof.

25 7. A method as claimed in claim 6, wherein methyl phenidate and melatonin
are applied simultaneously.

8. A method as claimed in claim 6, wherein methyl phenidate and melatonin
30 are applied subsequently.

9. A method as claimed in claim 8, wherein melatonin is administered following
the administration of methyl phenidate.

10. A pharmaceutical composition comprising, as active ingredients, methylphenidate and at least one of melatonin, a melatonin analogue, or one or more pharmaceutically acceptable salts or esters thereof, in conjunction with a pharmaceutically acceptable carrier.

5

11. A pharmaceutical composition according to claim 10 comprising, as active ingredients, methylphenidate and melatonin, in conjunction with a pharmaceutically acceptable carrier.

10

12. Use of methylphenidate and at least one of melatonin, a melatonin analogue, or one or more pharmaceutically acceptable salts or esters thereof as claimed in claim 1, wherein methylphenidate and at least one of melatonin, a melatonin analogue, or one or more pharmaceutically acceptable salts or esters thereof are comprised in separate forms of administration.

15

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/10827

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/4045 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HOBAN T F: "SLEEPLESSNESS IN CHILDREN WITH NEURODEVELOPMENTAL DISORDERS EPIDEMIOLOGY AND MANAGEMENT" CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 14, no. 1, July 2000 (2000-07), pages 11-22, XP001013140 ISSN: 1172-7047 abstract</p> <p style="text-align: center;">----- -/--</p>	1-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

12 February 2004

Date of mailing of the international search report

01/03/2004

Name and mailing address of the ISA
European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cattell, James

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/10827

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KIRBY KELLY ET AL: "DIAGNOSIS AND MANAGEMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN" CURRENT OPINION IN PEDIATRICS, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 13, no. 2, 2001, pages 190-199, XP001013123 ISSN: 1040-8703 abstract	1-12
P,A	WO 02/076452 A (POOGER PROPERTIES LTD ; KRUISINGA ROELOF JOHANNES HEND (NL)) 3 October 2002 (2002-10-03) claim 1	1-12
P,X	CECIL ET AL: "Melatonin for treatment of sleeping disorders in children with attention deficit hyperactivity disorder." EUR.J.PEDIATR., vol. 162, 2003, pages 554-555, XP002269839 3RD JUNE 2003 the whole document	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/10827

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02076452	A	03-10-2002	WO 02076452 A1	03-10-2002
			EP 1370259 A1	17-12-2003